That compares to an estimated 300 million euros of savings from Rituxan biosimilars alone in 2017. Drug companies such as Switzerland 's Roche are expected to be hit by the long-awaited threat of cut-price competition from biosimilar drugs, following regulatory approval of copycat versions of its biological cancer treatments. The approvals will increase the onus on the pharma firm to make a success of its new cancer drugs; Gazyva , Avastin and Tecentriq , as margins from sales of its established drugs come under pressure. Together, revenues from Roche 's Rituxan, Herceptin and Perjeta stood at CHF20.9bn ($ hundreds of millions ) for 2016 , though their combined sales are expected to fall 40% by 2016 .
Drug companies such as Switzerland 's Roche are expected to be hit by the long-awaited threat of cut-price competition from biosimilar drugs, following regulatory approval of copycat versions of its biological cancer treatments. The approvals will increase the onus on the pharma firm to make a success of its new cancer drugs; Gazyva , Avastin and Tecentriq , as margins from sales of its established drugs come under pressure. Together, revenues from Roche 's Rituxan, Herceptin and Perjeta stood at CHF20.9bn ($ hundreds of millions ) for 2016 , though their combined sales are expected to fall 40% by 2016 .